ArticleWorld journal of gastrointestinal oncology2025
Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced hepatocellular carcinoma (HCC) with ascites (AS) lacks reliable biomarkers for predicting treatment outcomes. The combined prognostic value of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) remains underexplored for novel therapies.
aimTo evaluate the clinical efficacy of combining intraperitoneal compound Kushen injection (CKI) with immunotherapy in patients with advanced HCC using a scoring system that combines SII and PNI.
methodsSII and PNI were calculated prior to treatment from peripheral blood samples, and critical values were determined by receiver operating characteristic analysis. SII-PNI scores were categorized as follows: 2, high SII (≥ 558.5) and low PNI (≤ 33.58); 1, high SII or low PNI; and 0, neither high SII nor low PNI. After immunotherapy combined with CKI, patients with advanced HCC were evaluated using the SII-PNI scoring criteria.
resultsThe SII-PNI score was significantly lower in patients without concomitant AS than in those with AS (
conclusionThe pretreatment SII-PNI score is an important indicator of treatment sensitivity for patients with advanced HCC receiving intraperitoneal CKI. It also represents a crucial basis for evaluating treatment efficacy and prognosis, aiding in the identification of high-risk groups and prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.